Publications by authors named "Joseph B Barney"
Article Synopsis
- Lymphangioleiomyomatosis (LAM) is a rare disease mainly affecting women of childbearing age, with limited data on how it interacts with pregnancy; the study aims to review existing literature on this topic.* -
- A systematic review of 175 publications resulted in 31 qualifying studies, revealing that women diagnosed with LAM during pregnancy face worse outcomes like pneumothorax and preterm delivery compared to those diagnosed beforehand.* -
- The review suggests a need for careful preconception counseling and management strategies for pregnant women with LAM to address the increased risks associated with the condition.*
In patients treated with repository corticotrophin injection (RCI) for pulmonary sarcoidosis, effective management of adverse events may improve adherence. However, management of adverse events may be challenging due to limitations in real-world clinical experience with RCI and available published guidelines.We surveyed 12 physicians with a modified Delphi process using three questionnaires.
View Article and Find Full Text PDFPulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations.
View Article and Find Full Text PDFIntroduction: Acthar was reported as effective for the treatment of pulmonary sarcoidosis in the 1950s. Use of drug waned due to cost and toxicity compared to prednisone. Recent interest has reemerged as an alternative to high dose oral glucocorticoids.
View Article and Find Full Text PDFRationale: Pulmonary venoocclusive disease (PVOD) is an uncommon cause of pulmonary arterial hypertension (PAH). However, unlike PAH, treatment options for PVOD are usually quite limited. The impact of the lung allocation score on access to transplantation for patients with PVOD and the clinical course of these patients have not been well-described.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to explore the experiences and long-term effects of severe sepsis on both survivors and their informal caregivers through qualitative interviews conducted in the UK and US.
- - Researchers conducted 39 interviews with 22 patients and 17 caregivers, focusing on themes such as awareness of severe sepsis, hospitalization experiences, ongoing impacts on patients, caregiver challenges, and post-sepsis support.
- - Findings revealed that patients' prior health influenced their experiences, with many reporting significant and lasting effects on their daily lives due to severe sepsis.
Sarcoidosis is characterised by non-caseating granulomas that secrete pro-inflammatory cytokines, including interleukin (IL)-12, IL-23, and tumour necrosis factor (TNF)-α. Ustekinumab and golimumab are monoclonal antibodies that specifically inhibit IL-12/IL-23 and TNF-α, respectively. Patients with chronic pulmonary sarcoidosis (lung group) and/or skin sarcoidosis (skin group) received either 180 mg ustekinumab at week 0 followed by 90 mg every 8 weeks, 200 mg golimumab at week 0 followed by 100 mg every 4 weeks, or placebo.
View Article and Find Full Text PDF